Are Antibiotics Bad for Your Kidneys?

Most antibiotics taken at standard doses by otherwise healthy people do not damage the kidneys. But a handful of antibiotic classes, particularly aminoglycosides, polymyxins, and vancomycin, carry well-documented kidney risks that climb sharply when doses are high, courses are long, or the patient already has compromised renal function. The story gets more complicated when you factor in drug combinations, underlying conditions, and even what antibiotics do to gut bacteria that help keep kidney stones at bay.

Which Antibiotics Pose the Greatest Risk

Not all antibiotics are created equal when it comes to the kidneys. The classes most consistently linked to kidney injury tend to be the ones reserved for serious infections, often in hospital settings where patients are already critically ill. That context matters: the sickest patients get the strongest drugs, and separating the drug’s effect from the disease’s effect is a recurring challenge in research.

Aminoglycosides (gentamicin, tobramycin, amikacin) are among the oldest known kidney-toxic antibiotics. They accumulate inside the cells of the kidney’s filtering tubes, disrupting the normal breakdown of fats and causing a buildup of damaged cellular material that eventually kills the cells.¹ Because aminoglycosides are excreted almost entirely by the kidneys, any decline in kidney function slows their clearance, which raises drug levels, which worsens the damage. It is a vicious feedback loop that makes careful dosing essential.

Polymyxins (colistin and polymyxin B) are another high-risk group. These are last-resort antibiotics used against multidrug-resistant bacteria, and their kidney toxicity rates are sobering. In one retrospective study of intensive care patients receiving polymyxin B, about a third developed kidney damage of varying severity, with longer treatment duration, higher body mass, and older age all independently raising the odds.² A larger study comparing the two polymyxins found that roughly four in ten patients developed acute kidney injury, with the rate climbing steeply as drug exposure increased.³

Vancomycin, widely used for serious staphylococcal infections, sits in a gray zone. On its own at properly monitored levels, the risk is moderate. But when it is combined with certain other antibiotics, the kidney risk jumps considerably, as we will see below.

Fluoroquinolones like ciprofloxacin occasionally cause a different pattern of kidney injury. Rather than directly poisoning tubular cells, ciprofloxacin can deposit crystals in the kidney tissue, triggering inflammation known as acute interstitial nephritis.⁴ This is relatively uncommon but worth knowing about, especially since fluoroquinolones are prescribed far more freely than aminoglycosides or polymyxins.

Even penicillins, among the safest antibiotics overall, have been linked to rare cases of acute interstitial nephritis.⁵ That said, the key word there is “rare.” For the vast majority of people taking standard penicillin-family drugs for common infections, the kidneys are not in meaningful danger.

How Antibiotics Actually Damage the Kidneys

Kidney injury from antibiotics is not a single thing. It comes in several distinct patterns, and the pattern depends on which drug is involved. A comprehensive review identified four main mechanisms: direct injury to the filtering tubes, inflammation between the tubes triggered by an immune response, obstruction of the tubes by drug crystals, and damage to the kidney’s tiny blood-filtering units called glomeruli.⁶

Direct tubular injury is the pattern seen with aminoglycosides and polymyxins. The drug enters the cells that line the kidney’s filtering tubes and interferes with their internal machinery. With aminoglycosides, the target is the cell’s waste-recycling system. With piperacillin/tazobactam, a commonly used broad-spectrum antibiotic, animal studies have shown that the drug triggers oxidative stress and damages the energy-producing structures inside kidney cells, ultimately pushing the cells toward death.⁷

Acute interstitial nephritis, by contrast, is an allergic-type immune reaction. It can happen with nearly any antibiotic but is best known with penicillins, cephalosporins, and fluoroquinolones. The immune system mistakenly attacks the kidney tissue surrounding the tubules, causing inflammation and swelling. This reaction is unpredictable; it does not depend on the dose the way tubular injury does, and it can occur even after a drug has been taken safely before.

Crystal-related injury is a more mechanical process. Some antibiotics or their breakdown products are poorly soluble in urine, and under the right conditions they crystallize inside the kidney’s tiny passageways. Ceftriaxone, a widely used injectable cephalosporin, can combine with calcium in the urine to form crystals that stick to the surface of tubular cells.⁸ This is especially relevant at high doses or when a patient is dehydrated. Sulfonamides and some antiviral drugs also cause crystal nephropathy, and the risk rises when urine volume is low or urine pH favors crystallization.⁹

When Drug Combinations Multiply the Risk

One of the sharpest kidney-safety signals in recent years involves the combination of vancomycin with piperacillin/tazobactam. Individually, each drug carries some renal risk. Together, the risk roughly doubles compared to vancomycin paired with other broad-spectrum antibiotics like cefepime or meropenem. A network meta-analysis pulling together data from multiple studies found that the vancomycin-plus-piperacillin/tazobactam combination carried about two and a half times the odds of acute kidney injury compared to vancomycin combined with cefepime.¹⁰ A separate analysis using a Japanese adverse-drug-reaction database found a very similar risk estimate for this combination.¹¹

What makes this finding so consequential is how often this combination is prescribed. In many hospitals, vancomycin plus piperacillin/tazobactam is a go-to regimen for patients with severe infections before culture results come back. In a large randomized trial, piperacillin/tazobactam was also linked to slower kidney recovery compared to meropenem among critically ill patients, with the kidneys recovering about a third as quickly while patients remained on the drug.¹² These findings have pushed many hospitals to reconsider whether cefepime or meropenem might be safer partners for vancomycin when empiric coverage is needed.

Antibiotics can also increase kidney risk indirectly through interactions with other medications a patient is already taking. A large population-based study found that people on statin therapy who were prescribed clarithromycin or erythromycin (macrolide antibiotics that slow the breakdown of statins) had a higher risk of hospitalization for acute kidney injury and for rhabdomyolysis, a condition where muscle tissue breaks down and floods the kidneys with protein. The absolute risk increase for kidney injury was about 1.3% compared to patients prescribed azithromycin, a macrolide that does not have the same interaction.¹³ If you take a statin and need an antibiotic, this is the kind of interaction worth asking your doctor about.

Who Is Most Vulnerable

Healthy young adults with normal kidney function taking a standard course of amoxicillin for a sinus infection face negligible kidney risk. The concern escalates with specific patient characteristics, many of which cluster together in hospital settings.

Older adults are disproportionately affected. The kidneys lose filtering capacity with age, meaning drugs that are cleared by the kidneys stick around longer and reach higher concentrations. Combine that with the polypharmacy common in elderly patients and the increased likelihood of dehydration, and the risk of antibiotic-induced kidney injury rises substantially.¹⁴

People with pre-existing kidney disease are in double jeopardy. Their kidneys are already working with reduced capacity, so the margin of safety for any nephrotoxic drug is narrower. Dosing must be carefully adjusted based on the patient’s actual kidney function to avoid accumulation and further damage.¹⁵

Diabetes and dehydration both independently raise the risk. A study tracking antibiotic-induced kidney injury found that patients who had diabetes had roughly 2.6 times the odds of developing nephrotoxicity, while those who were dehydrated on admission had about 3.4 times the odds. Being given a combination of nephrotoxic drugs approximately doubled the risk as well.¹⁶ Dehydration reduces blood flow to the kidneys and concentrates drug levels in the urine, making crystal formation and tubular damage more likely. Staying well-hydrated during any antibiotic course is one of the simplest protective measures available.

At the other end of the age spectrum, neonates are surprisingly exposed. A large multicenter study of over 2,100 newborns found that about three quarters received at least one nephrotoxic medication, with aminoglycosides being by far the most common. Neonates who received an aminoglycoside combined with another nephrotoxic drug had nearly five times the hazard of developing acute kidney injury compared to those not exposed to nephrotoxic medications.¹⁷ Neonatal kidneys are still maturing, which makes them especially sensitive to drug-induced harm.

Antibiotics and Kidney Stones

Beyond acute kidney injury, there is growing evidence that antibiotics may contribute to kidney stone formation through a less obvious route: by changing the gut bacteria that help regulate what ends up in your urine. One bacterium, Oxalobacter formigenes, normally lives in the colon and breaks down oxalate, a chemical that is a key ingredient in the most common type of kidney stone. When antibiotics wipe out this bacterium, more oxalate gets absorbed into the bloodstream, more oxalate ends up in the urine, and the conditions for calcium oxalate stone formation improve.¹⁸

A case-control study found that prior exposure to sulfa drugs, cephalosporins, fluoroquinolones, nitrofurantoin, and broad-spectrum penicillins was each associated with increased odds of developing kidney stones. The connection was not limited to one antibiotic class, which supports the idea that microbiome disruption, rather than any single drug’s chemistry, is the driving factor. Separately, researchers have noted that other types of gut bacteria can promote different stone types. Urease-producing bacteria, for instance, break down urea in a way that raises urine pH and encourages the formation of struvite stones.¹⁹

This microbiome angle is relatively new science, and it does not mean a single course of antibiotics will give you kidney stones. But for people who already have a history of calcium oxalate stones, the idea that repeated antibiotic courses might be chipping away at their protective gut flora is worth paying attention to. It is yet another reason to avoid unnecessary antibiotic use when the infection does not call for it.

How Kidney Damage Gets Detected

One frustrating reality of antibiotic-induced kidney injury is that the standard way we detect it is slow. Doctors typically rely on serum creatinine levels and urine output to identify acute kidney injury, but creatinine is a lagging indicator. By the time it rises enough to flag a problem, meaningful damage may already have occurred. This delay makes it harder to intervene early, especially in fast-moving hospital situations where antibiotics are being given at high doses around the clock.

Newer biomarkers are being studied that may detect kidney cell injury before creatinine changes. These include proteins released by damaged tubular cells and markers of the inflammatory or stress response within the kidney. Research into these markers specifically in the context of antibiotic-induced kidney injury has shown promise for earlier detection, though they are not yet standard in most clinical settings.²⁰ If these biomarkers eventually become routine, doctors would have a better window to adjust or switch drugs before permanent damage sets in.

Reducing the Risk in Practice

For critically ill patients receiving high-risk antibiotics, several strategies help keep the kidneys as safe as possible. Maintaining adequate hydration and blood flow to the kidneys with intravenous fluids is a baseline measure. On top of that, monitoring drug levels in the blood, reducing the total number of nephrotoxic drugs a patient is exposed to, and following antimicrobial stewardship principles are all considered core preventive strategies.²¹

For vancomycin specifically, how the drug is dosed and monitored makes a meaningful difference. Newer guidelines recommend targeting a measure of total daily drug exposure rather than simply checking trough levels before the next dose. This approach has been associated with lower rates of kidney injury compared to older trough-based dosing strategies.²² In practical terms, this means many hospitals have shifted to fewer blood draws timed at specific intervals and run through dosing software, rather than the old method of chasing a single number before each dose.

For outpatients, the calculus is simpler. If you have normal kidney function and your doctor prescribes a standard oral antibiotic for a routine infection, kidney damage is extremely unlikely. The useful things you can do are straightforward: stay well hydrated, especially with drugs known to crystallize in urine; mention all other medications you are taking so your doctor can flag interactions; and do not extend antibiotic courses beyond what is prescribed. If you have known kidney disease, diabetes, or are taking medications that stress the kidneys (like certain blood pressure drugs or anti-inflammatory painkillers), make sure your prescriber knows. Dose adjustments for reduced kidney function are well established for most antibiotics, but they only help if the prescriber has accurate information about your kidney status.

The Beta-Lactam Spectrum

Beta-lactam antibiotics, the enormous family that includes penicillins, cephalosporins, and carbapenems, deserve a closer look because they are the most commonly prescribed antibiotics worldwide and their kidney-safety profiles vary widely within the family. Penicillins have historically been considered quite safe for the kidneys, with renal toxicity appearing only rarely, usually as immune-mediated interstitial nephritis. Cephalosporins carry slightly more risk but still fall on the safer end of the spectrum. The carbapenems (like meropenem and imipenem) are reserved for resistant infections and are generally less nephrotoxic than aminoglycosides or polymyxins, though they are not risk-free in vulnerable patients.²³

Within this family, the mechanism of kidney injury involves the drug being transported into the cells of the kidney’s proximal tubules, where it can interfere with the cells’ energy production and trigger a chain of damage. The more efficiently a particular beta-lactam is pumped into these cells, the more nephrotoxic it tends to be. This is why some drugs within the same class are safer than others, and it also explains why blocking the transport pathway has been explored as a strategy to reduce kidney toxicity while preserving the drug’s infection-fighting ability.

This within-family variation is worth knowing about because patients and even some prescribers sometimes think of “penicillin-type drugs” as a single safety category. They are not. The differences matter, especially in hospitalized patients receiving intravenous formulations at high doses over extended periods.